ESR1 and breast cancer: Estrogen, the JAK/STAT inhibitor, Ruxolitinib, or inhibitors of other ERα and JAK/STAT coactivators could effectively treat AI-resistant patients or IFITM1-expressing breast cancer in combination [42].